» Articles » PMID: 33102757

Risk Factors for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients-Relationship to Smoking and Alcohol

Overview
Journal JGH Open
Specialty Gastroenterology
Date 2020 Oct 26
PMID 33102757
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: The purpose of this study was to identify lifestyle risk factors, such as cigarette smoking and alcohol consumption, in relation to the development of hepatocellular carcinoma (HCC) among chronic hepatitis C patients who have achieved a sustained virologic response (SVR).

Methods: This cross-sectional study was conducted between 2014 and 2017 using self-administered questionnaires and medical information at two tertiary hospitals in Osaka, Japan. Study subjects were chronic hepatitis C patients who had achieved SVR without HCC following antiviral treatment that was completed more than 1 year earlier. A logistic regression model was used to calculate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the development of post-SVR HCC for each factor.

Results: Of 202 participants, 18 patients were diagnosed with post-SVR HCC. After considering potential confounders, former drinkers at the time of SVR (OR, 9.51; 95% CI, 1.08-83.90) and patients with a history of gastric or duodenal ulcer (OR, 4.14; 95% CI, 1.37-12.46) were significantly associated with HCC. In addition, among patients with severe fibrosis, current smokers at the time of SVR had an increased OR for HCC compared with never smokers, with marginal significance (OR, 5.61; 95% CI, 0.97-32.63).

Conclusions: In chronic hepatitis C patients with severe fibrosis, continuing smoking after achieving SVR could be a risk factor for post-SVR HCC. The relationship between gastric or duodenal ulcer history and post-SVR HCC should be investigated further.

Citing Articles

Application of Indirect ELISA and PCR Techniques for Detecting of Hepatocellular Carcinoma using Des-gamma Carboxyprothrombin, Alpha-fetoprotein, and Thioredoxin Biomarkers.

Huy D, Khai N, Thinh T, Linh B, Minh N, Thuy V Mol Biotechnol. 2025; .

PMID: 39998774 DOI: 10.1007/s12033-025-01401-z.


Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection.

Karimi-Sari H, Lucas G, Zook K, Weir B, Landry M, Sherman S Viruses. 2024; 16(9).

PMID: 39339891 PMC: 11437464. DOI: 10.3390/v16091416.


Evaluation of Two-Assay Serological Testing Strategies for Anti-HCV Screening in Italian Populations: A Dual Screening Approach.

Zocca E, Seraceni S, Cafaro T, Cervone T, Cardarelli L, Valisi M Diagnostics (Basel). 2024; 14(6).

PMID: 38534991 PMC: 10969070. DOI: 10.3390/diagnostics14060570.


Tobacco Smoking and Gastrointestinal Cancer Risk.

Scherubl H Visc Med. 2022; 38(3):217-222.

PMID: 35814979 PMC: 9209969. DOI: 10.1159/000523668.

References
1.
El-Serag H, Kanwal F, Richardson P, Kramer J . Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016; 64(1):130-7. PMC: 4917456. DOI: 10.1002/hep.28535. View

2.
Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H . Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005; 40(2):148-56. DOI: 10.1007/s00535-004-1519-2. View

3.
Lin Z, Xin Y, Dong Q, Wang Q, Jiang X, Zhan S . Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3):726-36. DOI: 10.1002/hep.24105. View

4.
Kanwal F, Kramer J, Asch S, Chayanupatkul M, Cao Y, El-Serag H . Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017; 153(4):996-1005.e1. DOI: 10.1053/j.gastro.2017.06.012. View

5.
Hezode C, Lonjon I, Roudot-Thoraval F, Pawlotsky J, Zafrani E, Dhumeaux D . Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther. 2003; 17(8):1031-7. DOI: 10.1046/j.1365-2036.2003.01546.x. View